| Autor: |
Paul G, Richardson, Susanna J, Jacobus, Edie A, Weller, Hani, Hassoun, Sagar, Lonial, Noopur S, Raje, Eva, Medvedova, Philip L, McCarthy, Edward N, Libby, Peter M, Voorhees, Robert Z, Orlowski, Larry D, Anderson, Jeffrey A, Zonder, Carter P, Milner, Cristina, Gasparetto, Mounzer E, Agha, Abdullah M, Khan, David D, Hurd, Krisstina, Gowin, Rammurti T, Kamble, Sundar, Jagannath, Nitya, Nathwani, Melissa, Alsina, R Frank, Cornell, Hamza, Hashmi, Erica L, Campagnaro, Astrid C, Andreescu, Teresa, Gentile, Michaela, Liedtke, Kelly N, Godby, Adam D, Cohen, Thomas H, Openshaw, Marcelo C, Pasquini, Sergio A, Giralt, Jonathan L, Kaufman, Andrew J, Yee, Emma, Scott, Pallawi, Torka, Amy, Foley, Mariateresa, Fulciniti, Kyle, Hebert, Mehmet K, Samur, Kelly, Masone, Michelle E, Maglio, Andrea A, Zeytoonjian, Omar, Nadeem, Robert L, Schlossman, Jacob P, Laubach, Claudia, Paba-Prada, Irene M, Ghobrial, Aurore, Perrot, Philippe, Moreau, Hervé, Avet-Loiseau, Michel, Attal, Kenneth C, Anderson, Nikhil C, Munshi, Hillard, Lazarus |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
N Engl J Med |
| ISSN: |
1533-4406 |
| Popis: |
BACKGROUND: In patients with newly diagnosed multiple myeloma, the effect of adding autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib, and dexamethasone [RVD]), followed by lenalidomide maintenance therapy until disease progression, is unknown. METHODS: In this phase 3 trial, adults (18 to 65 years of age) with symptomatic myeloma received one cycle of RVD. We randomly assigned these patients, in a 1:1 ratio, to receive two additional RVD cycles plus stem-cell mobilization, followed by either five additional RVD cycles (the RVD-alone group) or high-dose melphalan plus ASCT followed by two additional RVD cycles (the transplantation group). Both groups received lenalidomide until disease progression, unacceptable side effects, or both. The primary end point was progression-free survival. RESULTS: Among 357 patients in the RVD-alone group and 365 in the transplantation group, at a median follow-up of 76.0 months, 328 events of disease progression or death occurred; the risk was 53% higher in the RVD-alone group than in the transplantation group (hazard ratio, 1.53; 95% confidence interval [CI], 1.23 to 1.91; P |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
